Repligen Corp
RGENRepligen Corp (RGEN) is a biotechnology company specializing in the development and manufacturing of bioprocessing technologies and systems. Founded in 1981, the company provides solutions for the production of biologic drugs, including filtration, chromatography, and purification products. Repligen serves biopharmaceutical and gene therapy companies worldwide, supporting the development, manufacturing, and commercialization of advanced biological medicines.
Company News
The filtration in biologics market is projected to experience significant growth from 2024 to 2034, driven by increasing demand for monoclonal antibodies, vaccines, and cell and gene therapies, with North America leading and Asia Pacific showing the fastest growth potential.
Repligen, a bioprocessing technology company, reported mixed Q4 results. While adjusted EPS exceeded expectations, GAAP gross margin declined significantly due to restructuring and other costs. The company is focused on product innovations and strategic acquisitions to drive growth.
BioLife Solutions, a leading developer and supplier of bioproduction tools and services for the cell and gene therapy market, has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors. Hunt's appointment is expected to strengthen BioLife's focus on extending its position as a provider of industry-leading so...
Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
